ENO1 has been proposed as a PCa biomarker by numerous proteomics (discussed below in detail), genomics, and functional studies, as well as a biomarker for glioma, neurocytoma, cholangiocarcinoma, lung, kidney, nasopharyngeal cancer, etc. (detailed description is given in Supplementary Table S3). This evidence concerns the gene ENO1 and posterior cortical atrophy.